IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
IceCure Medical (NASDAQ: ICCM), a developer of cryoablation technology for tumor treatment, released preliminary financial results for Q2 and H1 2025. The company expects Q2 2025 product sales of $525,000, with over $200,000 in delayed shipments moving to Q3 2025 due to temporary logistics issues related to the Israel-Iran conflict.
For H1 2025, product sales reached approximately $1.25 million, down from $1.65 million in H1 2024. The company maintains that order flow remained stable despite regional conflicts, with delays primarily affecting non-U.S. markets. U.S. operations continued normally due to sufficient ProSense® inventory. Complete Q2 and H1 2025 financial results will be released in August 2025.
IceCure Medical (NASDAQ: ICCM), sviluppatore di tecnologia di crioablazione per il trattamento dei tumori, ha diffuso i risultati finanziari preliminari per il secondo trimestre e il primo semestre del 2025. L'azienda prevede vendite di prodotti per 525.000$ nel Q2 2025, con oltre 200.000$ di spedizioni ritardate che saranno posticipate al Q3 2025 a causa di problemi logistici temporanei legati al conflitto tra Israele e Iran.
Per il primo semestre 2025, le vendite di prodotti hanno raggiunto circa 1,25 milioni di dollari, in calo rispetto a 1,65 milioni di dollari nello stesso periodo del 2024. L'azienda conferma che il flusso degli ordini è rimasto stabile nonostante i conflitti regionali, con i ritardi che hanno interessato principalmente i mercati fuori dagli Stati Uniti. Le operazioni negli USA sono proseguite normalmente grazie a un inventario sufficiente di ProSense®. I risultati finanziari completi per Q2 e H1 2025 saranno pubblicati nell'agosto 2025.
IceCure Medical (NASDAQ: ICCM), desarrollador de tecnología de crioablación para el tratamiento de tumores, publicó resultados financieros preliminares para el segundo trimestre y primer semestre de 2025. La compañía espera ventas de productos de 525,000$ en el Q2 2025, con más de 200,000$ en envíos retrasados que se trasladarán al Q3 2025 debido a problemas logísticos temporales relacionados con el conflicto Israel-Irán.
Para el primer semestre de 2025, las ventas de productos alcanzaron aproximadamente 1.25 millones de dólares, frente a 1.65 millones de dólares en el mismo periodo de 2024. La empresa mantiene que el flujo de pedidos se mantuvo estable a pesar de los conflictos regionales, con retrasos que afectaron principalmente a los mercados fuera de EE. UU. Las operaciones en EE. UU. continuaron normalmente gracias a un inventario suficiente de ProSense®. Los resultados financieros completos para Q2 y H1 2025 se publicarán en agosto de 2025.
IceCure Medical (NASDAQ: ICCM)는 종양 치료용 냉동 절제 기술 개발업체로, 2025년 2분기 및 상반기 예비 재무 결과를 발표했습니다. 회사는 2025년 2분기 제품 매출 52만 5천 달러를 예상하며, 이스라엘-이란 분쟁과 관련된 일시적 물류 문제로 인해 20만 달러 이상의 지연 배송분이 2025년 3분기로 이월될 것이라고 밝혔습니다.
2025년 상반기 제품 매출은 약 125만 달러로, 2024년 상반기의 165만 달러에서 감소했습니다. 회사는 지역 분쟁에도 불구하고 주문 흐름이 안정적이었다고 보고하며, 지연은 주로 미국 외 시장에 영향을 미쳤다고 설명했습니다. 미국 내 운영은 ProSense® 재고가 충분해 정상적으로 진행되었습니다. 2025년 2분기 및 상반기 전체 재무 결과는 2025년 8월에 발표될 예정입니다.
IceCure Medical (NASDAQ : ICCM), développeur de la technologie de cryoablation pour le traitement des tumeurs, a publié les résultats financiers préliminaires du deuxième trimestre et du premier semestre 2025. La société prévoit des ventes de produits de 525 000 $ au T2 2025, avec plus de 200 000 $ de livraisons retardées reportées au T3 2025 en raison de problèmes logistiques temporaires liés au conflit Israël-Iran.
Pour le premier semestre 2025, les ventes de produits ont atteint environ 1,25 million de dollars, en baisse par rapport à 1,65 million de dollars au premier semestre 2024. La société affirme que le flux de commandes est resté stable malgré les conflits régionaux, les retards affectant principalement les marchés hors États-Unis. Les opérations américaines se sont poursuivies normalement grâce à un stock suffisant de ProSense®. Les résultats financiers complets du T2 et du premier semestre 2025 seront publiés en août 2025.
IceCure Medical (NASDAQ: ICCM), ein Entwickler von Kryoablationstechnologie zur Tumorbehandlung, veröffentlichte vorläufige Finanzergebnisse für das zweite Quartal und das erste Halbjahr 2025. Das Unternehmen erwartet Produktverkäufe von 525.000 USD im Q2 2025, wobei über 200.000 USD an verzögerten Lieferungen aufgrund vorübergehender logistischer Probleme im Zusammenhang mit dem Israel-Iran-Konflikt in das Q3 2025 verschoben werden.
Für das erste Halbjahr 2025 erreichten die Produktverkäufe etwa 1,25 Millionen USD, gegenüber 1,65 Millionen USD im ersten Halbjahr 2024. Das Unternehmen betont, dass der Auftragseingang trotz regionaler Konflikte stabil blieb, wobei Verzögerungen hauptsächlich Märkte außerhalb der USA betrafen. Die US-Geschäfte liefen aufgrund ausreichender ProSense®-Bestände normal weiter. Die vollständigen Finanzergebnisse für Q2 und H1 2025 werden im August 2025 veröffentlicht.
- Order flow remained stable despite regional conflicts
- U.S. market operations continued normally with sufficient inventory
- Secured advance payments from global distributors for delayed shipments
- Q2 2025 product sales declined to $525,000 with $200,000 in delayed shipments
- H1 2025 product sales decreased to $1.25M from $1.65M in H1 2024
- Non-U.S. shipments faced temporary delays due to Israel-Iran conflict
Insights
IceCure reports Q2 2025 sales drop to $525K with $200K+ delayed to Q3; H1 sales fell 24% YoY to $1.25M.
IceCure's preliminary Q2 2025 financial results reveal several concerning trends despite the company's attempt to contextualize them. Product sales for Q2 2025 reached only approximately
More troubling is the six-month comparison: H1 2025 product sales totaled approximately
The company's statement about expecting "sales to fluctuate quarter-over-quarter due to timing of customer orders and shipments" appears to be an attempt to normalize what looks like deteriorating sales performance. The unusual step of issuing preliminary results while stating they "do not intend to issue preliminary financial results on a quarterly basis, unless otherwise warranted" suggests management felt compelled to get ahead of disappointing numbers.
The revenue decline is particularly concerning for a medical technology company in commercialization phase like IceCure, whose cryoablation technology for tumor removal should ideally be showing accelerating rather than decelerating adoption. The lack of growth despite having distribution channels in multiple global markets raises questions about product-market fit and competitive positioning that investors should monitor closely when full results are released in August.

The Company expects product sales of approximately
Payments for these orders, which were primarily from ProSense® distributors in global markets outside of the
As a result of lower than expected second quarter 2025 shipments, product sales for the six months ended June 30, 2025 was approximately
IceCure plans to report its second quarter and first half of 2025 comprehensive financial results in August 2025. The Company does not intend to issue preliminary financial results on a quarterly basis, unless otherwise warranted.
The foregoing is a preliminary estimate regarding the Company's revenue for the three and six-month period ended June 30, 2025. Moreover, this preliminary financial information has been prepared solely on the basis of information that is currently available to, and that is the responsibility of, management. IceCure Medical's independent registered public accounting firm has not audited nor reviewed, and does not express an opinion with respect to, this information. This preliminary financial information is based upon the Company's estimates, is not a comprehensive statement of the Company's revenue for the three and six-month period ended June 30, 2025 and remains subject to, among other things, the completion of the Company's financial closing procedures, final adjustments, and completion of the Company's internal review as of and for the six month period ended June 30, 2025, which may impact the results and expectations set forth above.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the Company's preliminary financial results as of and for the three and six months ended June 30, 2025; and expected delivery of shipments during July 2025 for product scheduled for delivery during the second quarter of 2025. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecure-reports-preliminary-financial-results-for-the-three-and-six-months-ended-june-30-2025-302497548.html
SOURCE IceCure Medical